Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jamjoom Pharmaceuticals Factory Co Buyback Yield % Chart
SAU:4015 vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jamjoom Pharmaceuticals Factory Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jamjoom Pharmaceuticals Factory Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jamjoom Pharmaceuticals Factory Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Jamjoom Pharmaceuticals Factory Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jamjoom Pharmaceuticals Factory Co (SAU:4015) has a Buyback Yield % of 0.00 as of Jul. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jamjoom Pharmaceuticals Factory Co and its competitors. According to the industry distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #999999 out of 289 companies in the Drug Manufacturers industry.
Is Jamjoom Pharmaceuticals Factory Co's Buyback Yield % too high?
Jamjoom Pharmaceuticals Factory Co's current Buyback Yield % is 0.00. Based on the distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #999999 out of 289 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jamjoom Pharmaceuticals Factory Co has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jamjoom Pharmaceuticals Factory Co's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #999999 out of 289 companies for Buyback Yield %. This places Jamjoom Pharmaceuticals Factory Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jamjoom Pharmaceuticals Factory Co and its competitors. Jamjoom Pharmaceuticals Factory Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jamjoom Pharmaceuticals Factory Co stock overvalued right now?
Based on GuruFocus' analysis, Jamjoom Pharmaceuticals Factory Co (SAU:4015) is currently considered Modestly Undervalued. The stock's GF Value™ is ﷼182.78, compared to a current price of ﷼138.90 — trading 24% below its estimated fair value. The current Buyback Yield % is 0.00. Jamjoom Pharmaceuticals Factory Co's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Jamjoom Pharmaceuticals Factory Co (SAU:4015), the current Buyback Yield % is 0.00 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jamjoom Pharmaceuticals Factory Co (SAU:4015) Overvalued in 2026?
Based on GuruFocus' analysis, Jamjoom Pharmaceuticals Factory Co stock appears to be undervalued.
The current stock price of ﷼138.90 is trading 24% below its estimated GF Value™ of ﷼182.78.
GuruFocus considers Jamjoom Pharmaceuticals Factory Co to be Modestly Undervalued.
Key valuation signals for SAU:4015:
Buyback Yield %: 0.00
GF Value™: ﷼182.78 vs. price of ﷼138.90 (24% below fair value)
No single metric tells the full story. See the SAU:4015 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jamjoom Pharmaceuticals Factory Co Business Description
Jamjoom Pharmaceuticals Factory Co is engaged in producing human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer and acidity, treatment of various skin infections, cancer diseases, eye drops and ointments and cosmeceuticals. Geographically the company has a presence in the Kingdom of Saudi Arabia, the Gulf, Iraq, Egypt, North Africa, and other export markets.
75GF Score
Get the complete analysis for SAU:4015
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4015 has been successfully added to your 
